|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
1999
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A08AB01
|
|
gptkbp:bioavailability
|
<1% (systemic)
|
|
gptkbp:brand
|
gptkb:Alli
gptkb:Xenical
|
|
gptkbp:CASNumber
|
96829-58-2
|
|
gptkbp:chemicalClass
|
lipase inhibitor
|
|
gptkbp:contraindication
|
cholestasis
chronic malabsorption syndrome
|
|
gptkbp:discoveredBy
|
gptkb:Roche
|
|
gptkbp:discoveredIn
|
1980s
|
|
gptkbp:effect
|
reduces dietary fat absorption
|
|
gptkbp:eliminationHalfLife
|
1-2 hours
|
|
gptkbp:excretion
|
feces
|
|
gptkbp:hasMolecularFormula
|
C29H53NO5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
orlistat
|
|
gptkbp:interactsWith
|
gptkb:cyclosporine
gptkb:levothyroxine
fat-soluble vitamins
|
|
gptkbp:KEGGID
|
D00432
|
|
gptkbp:legalStatus
|
prescription (varies by country)
|
|
gptkbp:marketedAs
|
gptkb:Switzerland
|
|
gptkbp:mechanismOfAction
|
lipase inhibitor
|
|
gptkbp:MedlinePlusID
|
a601244
|
|
gptkbp:metabolism
|
gastrointestinal tract
|
|
gptkbp:molecularWeight
|
495.73 g/mol
|
|
gptkbp:origin
|
derived from lipstatin
|
|
gptkbp:patent
|
gptkb:Roche
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
B3 (Australia)
|
|
gptkbp:prescriptionStatus
|
over-the-counter (Alli, US)
prescription-only (Xenical, US)
|
|
gptkbp:PubChem_CID
|
3034010
CHEMBL120
DB01083
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
abdominal pain
flatulence
fecal urgency
oily spotting
|
|
gptkbp:UNII
|
95M8R751W8
|
|
gptkbp:usedFor
|
obesity treatment
|
|
gptkbp:bfsParent
|
gptkb:Fatty_Acid_Synthase
|
|
gptkbp:bfsLayer
|
6
|